Clinical Trials Browser

Completed × Temozolomide × Breast × Clear all

Breast Neoplasms

NCT03150810 2024-12-20

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

BreastGastrointestinalGynecologicHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01618136 2023-06-18

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Phase 1/2 Completed

41 enrolled

BreastGynecologicLymphoidOther hematologic neoplasm

Ovarian Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Triple Negative Breast Neoplasms

NCT01506609 2021-10-25

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Phase 2 Completed

294 enrolled 19 charts

Breast

Breast Neoplasms

NCT00617539 2018-04-20

Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases

Phase 2 Completed

30 enrolled 10 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT00526617 2017-11-21

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Phase 1 Completed

41 enrolled

BreastDermatologicGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms

NCT00831545 2017-05-09

Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)

Phase 2 Completed

162 enrolled

BreastDermatologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT00614978 2012-09-19

LAPTEM

Phase 1 Completed

18 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00194766 2007-11-14

Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer

Phase 2 Completed

35 enrolled

BreastSarcoma

Breast Neoplasms, Sarcoma

Clinical Trials

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)

LAPTEM

Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer